Dublin, March 31, 2022 (GLOBE NEWSWIRE) -- The "Labware Market - Global Outlook & Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering. The development of the laboratory glassware market is linked with the growth of industries like petrochemicals, polymer chemistry, and pharmaceuticals. Numerous manufacturers of laboratory glassware majorly rely on exports for commercial accomplishment. Factors such as the increasing number of R&D laboratories, rising demand for plasticware and glassware products for clinical use in hospitals and forensic laboratories as they are lightweight, recyclable, cost-effective, and non-breakable, and government support in the field of pharmaceutical and drug discovery are anticipated to be the key drivers for the growth of the global labware market in the coming years.

By end-user, the market is classified into research & academic institutions, hospitals & diagnostic centers, biotechnology industry & pharmaceutical, contract research organizations, food & beverage industry, and others. The research & academic institutions segment is the largest segment and accounted for a revenue share of 30.18% in 2021. The pipettes segment dominated the market and accounted for a highest share in 2021.

In North America, the rising number of diagnostic tests, increased usage of laboratory consumables, and introduction of specially designed plasticware are key factors that are driving the growth of the market in the region. The APAC labware market is the fastest growing in the world. Developing countries such as India are planning to initiate a nearly $1.3 billion fund to encourage businesses to manufacture pharmaceutical ingredients domestically by 2023. The country supplies a substantial share of the global demand for multiple vaccines and accounts for the second-largest pharmaceutical and biotech workforce globally.

The growth of players in the market depends on its condition, economic growth, and industry development. Exporting through an intermediary such as a distributor or importer is still the key channel for exporters from developing countries. Key Vendors

Key Topics Covered: 1 Research Methodology 2 Research Objectives 3 Research Process 4 Scope & Coverage 4.1 Market Definition 4.2 Base Year 4.3 Scope of the Study 4.4 Market Segmentation 5 Report Assumptions & Caveats 5.1 Key Caveats 5.2 Currency Conversion 5.3 Market Derivation 6 Market at a Glance 7 Introduction 7.1 Overview 7.2 Global Macroeconomic Overview 7.2.1 Macroeconomic Overview 7.2.2 Real GDP Growth 7.3 Global Healthcare Industry Overview 7.4 Value Chain Analysis 7.4.1 Raw Material/Design /Equipment Suppliers 7.4.2 Manufacturers 7.4.3 Distributors/Dealers 7.4.4 Retailers 7.4.5 End-Users 7.5 Impact of Covid-19 8 Market Opportunities & Trends 8.1 Increasing Shift from Glass to Plastic Labware 8.2 Point-Of-Care Testing Diagnostics 8.3 Advancements in Labware 9 Market Growth Enablers 9.1 Increasing Demand for Plastic Labware 9.2 Rising Research in Biotechnology & Pharmaceutical Industries 9.3 Investment in Plastic Labware 10 Market Restraints 10.1 Equipment Calibration 10.2 Brittle Nature of Glassware 11 Market Landscape 11.1 Market Size & Forecast 11.2 Five Forces Analysis 11.2.1 Threat of New Entrants 11.2.2 Bargaining Power of Suppliers 11.2.3 Bargaining Power of Buyers 11.2.4 Threat of Substitutes 11.2.5 Competitive Rivalry 12 Product 12.1 Market Snapshot & Growth Engine 12.2 Market Overview 12.3 Pipettes 12.4 Burettes 12.5 Beakers 12.6 Flasks 12.7 Test Tubes 13 Material Type 13.1 Market Snapshot & Growth Engine 13.2 Market Overview 13.3 Plasticware 13.4 Glassware 13.5 Disposable 14 End-user 14.1 Market Snapshot & Growth Engine 14.2 Market Overview 14.3 Research & Academic Institutions 14.3.1 Market Overview 14.3.2 Market Size & Forecast 14.3.3 Market by Geography 14.4 Hospitals & Diagnostic Centers 14.5 Biotechnology Industry & Pharmaceutical 14.6 Contract Research Organizations 14.7 Food & Beverage Industry 15 Geography 15.1 Market Snapshot & Growth Engine 15.2 Geographic Overview

For more information about this report visit https://www.researchandmarkets.com/r/f942uq

One day after Boeing (NYSE: BA) stock bounced higher on news of a big 737 plane sale to the parent company of British Airways and Iberia (the International Consolidated Airlines Group), shares of the airplane-building juggernaut are falling 7.2% as of 1:10 p.m. ET. The reason: Boeing may be encountering turbulence at higher altitudes. Earlier on Thursday, the big news around Boeing was the company's announcement that International Airlines Group has agreed to buy 25 Boeing 737-8-200 aircraft and 25 737 MAX 10 jetliners -- and taken out an option to buy as many as 100 more planes besides.

Shares of the artificial intelligence lender Upstart Holdings (NASDAQ: UPST) traded more than 16% lower as of 11:14 a.m. ET today after it received yet another downgrade from Wall Street. Wedbush analyst David Chiaverini maintained his underperform rating on Upstart but lowered his price target from $20 to $15 per share. The lower price target comes just a week after Chiaverini lowered his price target on Upstart from $35 to $20.

Yahoo Finance Live anchors discuss allegations that Elon Musk sexually harassed a flight attendant in 2016.

When Berkshire Hathaway (NYSE: BRK.A)(NYSE: BRK.B) CEO Warren Buffett buys or sells shares of a company, Wall Street and investors tend to pay close attention. Since becoming CEO in 1965, he's overseen the creation of more than $680 billion in shareholder value and delivered an average annual return of 20.1% for Berkshire's Class A (BRK.A) shareholders (himself included).

Over the past month, the odds of a home price correction spiked. That's according to an analysis CoreLogic ran for Fortune this week.

Shares of Pfizer (NYSE: PFE) were up 2.5% as of 11:35 a.m. ET on Friday after jumping as much as 4% earlier in the day. Meanwhile, the stocks of two other COVID-19 vaccine makers were declining. Moderna's (NASDAQ: MRNA) shares were down 4.7%.

Yahoo Finance Live anchors discuss second-quarter earnings for Deere.

In this article, we discuss 10 buy-the-dip stocks to buy according to billionaire Ken Fisher. If you want to skip our detailed analysis of Fisher’s stock selection and the current sell-off in tech, go directly to 5 Best Buy-the-Dip Tech Stocks According to Billionaire Ken Fisher. The tech-heavy Nasdaq Composite is down 27% in 2022 […]

Shares of Nvidia (NASDAQ: NVDA) continued to tumble on Friday, falling as much as 8%. Wells Fargo analyst Aaron Rakers lowered his price target on Nvidia to $250, down from $370, while maintaining his overweight (buy) rating on the stock, according to The Fly.

When legends speak, people listen – and few investors match the legendary status of Ray Dalio. The founder of Bridgewater Associates has built his firm from a 2-room apartment operation into the world’s largest hedge fund, with more than $150 billion in assets under management, and a net gain exceeding $46 billion. Dalio believes that the next two to four years will see our global economic and political systems change in ways that are unpredictable now. And the key to survival, for investors, ma

In early trading Friday, stock markets attempted to make a comeback and at least end a losing week on a winning note. As of 12:25 p.m. ET, shares of Rivian Automotive (NASDAQ: RIVN) are off 4.9%, Nikola (NASDAQ: NKLA) stock is down 5.8%, and Lucid Group (NASDAQ: LCID) -- the beneficiary of positive news as recently as yesterday -- is giving back most of its gains, and leading the sector 6.8% lower today.

Cathie Wood is a long-time Tesla bull, but the stock isn't the largest holding in Wood's ARK Innovation ETF anymore.

Athersys Inc's (NASDAQ: ATHX) partner, Healios K.K. has reported topline results for its Japan ischemic stroke study, TREASURE. The study included patients with moderate to moderate-severe ischemic stroke administered a single dose of MultiStem cells (invimestrocel) or placebo by intravenous infusion within 18-36 hours of the event. The primary endpoint, Excellent Outcome at 90 days, did not reach statistical significance in this population. Overall, consistent improvement in essentially all mea

Nio (NYSE: NIO) shares began trading on the main board of the Singapore stock exchange today prior to the opening of the U.S. markets. After initially popping 20% early, the new shares ended up closing in Singapore about 2.4% higher, according to Barron's.

Yahoo Finance's Dan Howley details the latest information surrounding assault claims against Tesla CEO Elon Musk and how that may be affecting the billionaire's Twitter acquisition deal.

Your retirement savings are $1 million. You want $100,000 of yearly retirement income, including Social Security. Is that doable without tons of risk?

In this article, we discuss 6 stocks that Warren Buffett is selling in 2022. If you want to see more stocks that the billionaire sold, click Warren Buffett is Selling These 3 Stocks in 2022. Warren Buffett, the chief of Berkshire Hathaway, is perhaps the most renowned financier in the investment world, with decades of […]

The veteran tech giant just completed a multi-year turnaround. Here's the investment opportunity with the new IBM.

In this article, we discuss Michael Burry’s short position in Apple Inc. (NASDAQ:AAPL) and the 5 stocks he is selling in 2022. If you want to skip our analysis of Burry’s history, investment philosophy, and hedge fund performance, go directly to Michael Burry Is Selling These 3 Stocks in 2022. Michael Burry was born on […]

(Bloomberg) -- It’s been hard to watch, impossible to predict and a nightmare to trade. But has the S&P 500’s slide been an unqualified panic to date? By some measures no, and that might bode poorly for equities in the near term. Most Read from BloombergOne of the World’s Frothiest Housing Markets Turned Into a Seller’s Headache OvernightElon Musk Gets Defensive Over Twitter Meme as Harassment Report SurfacesApple Shows AR/VR Headset to Board in Sign of Progress on Key Project Stocks Avert Bear